Evidence map›Paper›PMID 31307981›Full record

ArticleAntimicrobial agents and chemotherapy2019

Synergistic Combinations and Repurposed Antibiotics Active against the Pandrug-Resistant Klebsiella pneumoniae Nevada Strain.

Thea Brennan-Krohn, James E Kirby

Abstract readLetter
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Colistin: Lights and Shadows of an Older Antibiotic.Molecules (Basel, Switzerland) · 2024
    Review
  6. Article
  7. A panel of diverseMicrobial genomics · 2023
    Article
  8. Synthesis of 4-Tetrahedron · 2023
    Article
  9. Synthesis, Antibacterial and Antiribosomal Activity of the 3Antibiotics (Basel, Switzerland) · 2022
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. New strategies and structural considerations in development of therapeutics for carbapenem-resistant Enterobacteriaceae.Translational research : the journal of laboratory and clinical medicine · 2020
    Review
  17. Apralogs: Apramycin 5-Journal of the American Chemical Society · 2020
    Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Thea Brennan-KrohnDepartment of Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
James E KirbyDepartment of Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA jekirby@bidmc.harvard.edu.

Funding

Antibacterial Resistance Leadership Group (ARLG)UM1AI104681 · NIAID · DUKE UNIVERSITY · PI Vance G. Fowler, Henry F HENRY CHAMBERS · 2013 to 2026
$180.8M
INFECTIOUS DISEASE AND BASIC MICROBIOLOGICAL MECHANISMST32AI007061 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Marcia B Goldberg · 1985 to 2026
$12.1M
Antimicrobial Synergy for Carbapenem-Resistant Enterobacteriaceae - Administrative SupplementK08AI132716 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BRENNAN-KROHN, THEA · 2018 to 2022
$916k
Apramycin scaffold exploration using novel glycochemistry and SAR studies to enhance activity against Acinetobacter baumannii and other multidrug-resistant Gram-negative pathogensR21AI142040 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI KIRBY, JAMES E, O'DOHERTY, GEORGE A · 2019 to 2020
$476k
Fusidic acid derivatization to enhance entry into Gram-negative pathogensR21AI146485 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI KIRBY, JAMES E, O'DOHERTY, GEORGE A · 2019 to 2020
$475k
NIAID NIH HHS K08 AI132716NIAID NIH HHS R21 AI142040NIAID NIH HHS R21 AI146485NIAID NIH HHS T32 AI007061NIAID NIH HHS UM1 AI104681
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AminoglycosidesAnti-Bacterial Agentsbeta-Lactamasesbeta-LactamsColistinDrug CombinationsDrug RepositioningDrug Resistance, Multiple, BacterialDrug SynergismFluoroquinolonesFusidic AcidGene ExpressionGlycopeptidesHumansKlebsiella InfectionsKlebsiella pneumoniaeAminoglycosidesAnti-Bacterial Agentsbeta-lactamase NDM-1beta-Lactamasesbeta-LactamsColistinDrug CombinationsFluoroquinolonesFusidic AcidGlycopeptidesLincosamidesMacrolidesantimicrobial resistanceapramycincarbapenem-resistant Enterobacteriaceaecolistinmultidrug resistanceNDM-1repurposedspectinomycinsynergy

Identifiers

PMID31307981
PMCPMC6709503

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.